MOLDCARE used in Stereotactic Ablative Body Radiotherapy for breast cancer

"Ablative Radiotherapy (SABR) as primary treatment in inoperable and elderly women with breast"
(De Haro Piedra R**1, Velázquez Miranda S***1, Rodríguez García E**1, Muñoz Carmona DM**1
**Servicio de Oncología Radioterápica Hospital Universitario Virgen del Rocío, Sevilla, España
***Servicio de Física Médica Hospital Universitario Virgen del Roció, Sevilla.
1 GiaCaMama Grupo de Investigación Avanzada en Cáncer de Mama. (EC Fase II PI 0113 16 Consejería de Salud))

This study was presented in ESTRO 2023. MOLDCARE (BR 3, 60cm x 60cm) is used with a breast stereotactic prototype with ribs dampening (developed and patented in their hospital and co-developed with the company AnatGe).

From June 2017 to June 2022, treatment with SABR was performed to 37 patients.
Regarding the response, 73% of the treated patients are in complete response (27 patients), 10.8% in partial response (4 patients), 10.8% (4 patients) with stable disease and only 5.4% in progression (2 patients).

This Poster states:
Stereotactic Ablative Body Radiotherapy treatment of the breast cancer using MOLDCARE has proven to be a safe, effective treatment, with excellent local control.

For more information about the study, please refer to the original documents as attached.

<Poster>
Ablative Radiotherapy (SABR) as primary treatment in inoperable and elderly women with breast cancer.pdf

<Summary>
Summary of Ablative Raditherapy (SABR) as primary treatment in inoperable and elderly women with breast cancer.pdf